NCT01865877 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Cervantes Arriaga A, Rodríguez Violante M, Camacho Ordóñez A, González Latapi P, López Ruiz M, Estrada Bellmann I, Zúñiga Ramírez C, Otero Cerdeira E
[Time from motor symptoms onset to diagnosis of Parkinson's disease in Mexico]. Gac Med Mex. 2014 Dec;15
Cervantes-Arriaga A, Rodríguez-Violante M, López-Ruiz M, Estrada-Bellmann I, Zuñiga-Ramírez C, Otero-Cerdeira E, Camacho-Ordoñez A, González-Latapi P, Morales-Briceño H, Martínez-Ramírez D
[Profile characterization of Parkinson's disease in Mexico: ReMeP

Motor, Non-motor and Genetic Determinants of Progression and Complications in Parkinson's Disease: A Multicenter Cohort Study in Mexican Population (ReMePArk)

Details for clinical trial NCT01865877

Clinical trial NCT01865877 - References